<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "ranitidine liq ORAL>
<dose><value>150</value>
<value>300</value>
</dose><route><value>PO</value>
</route><form><value>liq ORAL</value>
</form><drug><value>ranitidine liq ORAL</value>
</drug><strength><value>15 mg/mL</value>
</strength><frequency><value>DAILY</value>
<value>BID</value>
<value>HS</value>
<value>ONCE</value>
</frequency><instruction><value></value>
<value>Administer pre-operatively.</value>
<value>DAY 1 of 21. If oral ranitidine has not been taken by patient as instructed, administer 60 minutes pre-PACLitaxel. May be administered by IV route.</value>
<value>DAY 1 of 21. May be administered by IV route.</value>
<value>DAY 1 of 7. If oral ranitidine has not been taken by patient as instructed, administer 60 minutes pre-PACLitaxel. May be administered by IV route.</value>
<value>DAY 1 of 7. May be administered by IV route.</value>
</instruction><volume><value></value>
</volume><units><value>mg</value>
</units><additionalnotes><value></value>
</additionalnotes><population><value></value>
<value>Adjuvant PACLitaxel/CARBOplatin. Non-Small Cell Lung Cancer</value>
<value>PACLitaxel / CARBOplatin. Advanced / Metastatic Non-Small Cell Lung Cancer</value>
<value>PACLitaxel/CARBOplatin (Weekly) and concurrent RT. Non-Small Cell Lung Cancer.</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>alcohol free formulation</value>
<value></value>
</backgroundinformation><prninformation><value></value>
<value>YES</value>
</prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antiulcer Agents and Acid Suppressants, Histamine H2-Antagonists</value>
</ahfsname><highalert><value></value>
</highalert><maximumprndose><value></value>
</maximumprndose></drug>